Vantage Biosciences, a clinical stage biotechnology company advancing innovative therapies for diabetic eye diseases, today announced that the first patient has been successfully dosed in its Phase 2 clinical study evaluating VX-01, an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR).
Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of blindness among working-age adults. Without timely intervention, NPDR can progress to more severe stages of diabetic eye disease, increasing the risk of vision loss.
This milestone marks a significant step forward in the clinical development of VX-01, potentially the first oral treatment for this condition, designed to target the inflammatory mechanisms underlying NPDR progression.
“We are pleased to initiate patient dosing in this important Phase 2 study, which evaluates VX-01 as a potential early intervention for diabetic retinopathy,” said Alek Safarian, Co-Founder and Chairman of Vantage Biosciences. “By targeting the disease at an earlier stage, VX-01 has the potential to slow or prevent progression to more severe forms of diabetic retinopathy, reducing the likelihood that patients will require invasive treatments in the future.”
The Phase II study is expected to read out in 2027 and is being run at 27 sites across the US, Australia, and a number of Southeast Asian countries.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
